Innovation1 Biotech Inc. (IVBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 218.99 Thousand USD | -26.61% |
| 2022 | 298.42 Thousand USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q1 | 22.36 Thousand USD | -90.98% |
| 2023 FY | 218.99 Thousand USD | -26.61% |
| 2023 Q4 | 218.99 Thousand USD | 97.62% |
| 2023 Q3 | 110.81 Thousand USD | 0.0% |
| 2023 Q2 | 110.81 Thousand USD | 395.56% |
| 2022 Q3 | 350.09 Thousand USD | -12.59% |
| 2022 Q1 | - USD | 0.0% |
| 2022 FY | 298.42 Thousand USD | 0.0% |
| 2022 Q2 | 400.5 Thousand USD | 0.0% |
| 2022 Q4 | 248.03 Thousand USD | -29.15% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | 80.501% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | 83.05% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 99.499% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -2089.99% |
| Better Therapeutics, Inc. | 10.34 Million USD | 97.884% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -61.029% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -82.041% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 97.48% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 99.552% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 94.15% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 99.229% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.855% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | 75.974% |
| Molecular Templates, Inc. | 9.74 Million USD | 97.752% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 88.3% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 98.851% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 94.778% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 99.79% |
| Statera Biopharma, Inc. | 11.43 Million USD | 98.084% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | 70.082% |
| Trevena, Inc. | 35.23 Million USD | 99.378% |
| Vaxxinity, Inc. | 13.26 Million USD | 98.349% |
| Vaccinex, Inc. | 26 Thousand USD | -742.304% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |